0001104659-14-051553.txt : 20140715 0001104659-14-051553.hdr.sgml : 20140715 20140715104855 ACCESSION NUMBER: 0001104659-14-051553 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140715 DATE AS OF CHANGE: 20140715 EFFECTIVENESS DATE: 20140715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Esperion Therapeutics, Inc. CENTRAL INDEX KEY: 0001434868 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-221046 FILM NUMBER: 14974970 BUSINESS ADDRESS: STREET 1: 3891 RANCHERO DRIVE, SUITE 150 CITY: ANN ARBOR STATE: MI ZIP: 48108 BUSINESS PHONE: 734-887-3903 MAIL ADDRESS: STREET 1: 3891 RANCHERO DRIVE, SUITE 150 CITY: ANN ARBOR STATE: MI ZIP: 48108 FORMER COMPANY: FORMER CONFORMED NAME: HDL THERAPEUTICS INC DATE OF NAME CHANGE: 20080513 D 1 primary_doc.xml X0707 D LIVE 0001434868 Esperion Therapeutics, Inc. 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 734-887-3903 DELAWARE HDL Therapeutics, Inc. HDL THERAPEUTICS INC Corporation true Tim M. Mayleben 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 Executive Officer Director Roger S. Newton 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 Director Patrick Enright 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 Director Dov A. Goldstein 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 Director Antonio M. Gotto, Jr. 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 Director Daniel Janney 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 Director Mark E. McGovern 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 Director Gilbert S. Omenn 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 Director Nicole Vitullo 3891 Ranchero Drive, Suite 150 Ann Arbor MI MICHIGAN 48108 Director Pharmaceuticals Decline to Disclose 06b false 2014-06-30 false true false 0 Indefinite 0 Indefinite Issued a warrant to purchase common stock that is exercisable in connection with a Loan and Security Agreement. See Form 8-K filed with the SEC on July 2, 2014 for additional details. false 1 0 0 0 false Esperion Therapeutics, Inc. /s/ Tim M. Mayleben Tim M. Mayleben President and Chief Executive Officer 2014-07-14